Cognivia, an innovative AI company based in Wallonia, Belgium, dedicated to reshaping pharmaceutical and biotech clinical research through cutting-edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d'Investissement) and WE (Wallonie Entreprendre) have committed strategic investments to drive Cognivia's mission to "quantify the power of the mind" to optimize and accelerate drug development programs. This infusion of capital will allow Cognivia to deploy its predictive clinical trial solutions that decode the relationship between patient traits and behaviors, thus expediting the development of innovative treatments for patients globally.
Addressing critical challenges in drug development
Cognivia's solutions target critical areas that have historically posed significant challenges to drug development, such as the placebo response and medication adherence in clinical trials. Unlike any other, Cognivia is pioneering a quantitative understanding of patients as individuals and integrating these insights into the analysis of clinical trial data and/or optimization of patient engagement strategies. For instance, Placebell utilizes predictive algorithms to mitigate the negative impact of the placebo response, enhancing the study power of clinical trials, resulting in increased success rates and reduced clinical trial timelines and costs. Compl-AI predicts the risk of non-compliance and dropout of a patient at screening and during your clinical trial, helping to strengthen and personalize patient engagement strategies.
Investment to drive market expansion
The capital raised will catalyze Cognivia's endeavors to introduce its groundbreaking solutions to the market and cement a robust presence in the United States. Through the expansion of its team and the establishment of a subsidiary in the US, Cognivia seeks to foster enhanced commercial and R&D collaborations. In the near future, we plan to fortify our network through strategic alliances, bolstering our advisory board with new members, and building out teams in both the US and EU. This strategic maneuver is in perfect alignment with Cognivia's steadfast dedication to becoming a leading partner for pharmaceutical and biotechnology companies, empowering them to develop efficacious treatments to address unmet patient needs.
Pioneering transformation in healthcare
"Cognivia's strategic alliances with Vesalius Biocapital IV, SFPIM, and WE signify a pivotal moment in our quest to transform the industry through a unique blend of decades-long industry experience and advanced AI," remarked Dominique Demolle, CEO/Co-founder of Cognivia. "With this investment and the welcomed addition of new members to our operational team and Company Board and Strategic Advisory Committee, to be announced soon, we are poised to accelerate our efforts in delivering groundbreaking approaches that empower clinicians, researchers, and industries to make informed, data-driven decisions, ultimately enhancing outcomes for patients and stakeholders worldwide."
Unlocking Wallonia's innovation ecosystem
Cognivia's success story underscores Wallonia's position as a global leader in AI and biotech innovation, showcasing the region's capacity to nurture and support groundbreaking ventures. By aligning with Cognivia's vision and investing in Wallonia, foreign investors have the opportunity to be part of a transformative journey that promises both financial returns and societal impact. Together, let us unlock the full potential of Wallonia's innovation ecosystem and shape a brighter future for healthcare worldwide
Linked articles
Related articles
European patent office grants patent for Bioxodes' BIOX-101
Aerospacelab breaks ground on europe's largest satellite manufacturing facility
Belgium's offshore energy revolution: government commends progress on energy island project
